These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9667674)

  • 1. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.
    Lissoni P; Fumagalli L; Rovelli F; Brivio F; Di Felice G; Majorca F
    Br J Cancer; 1998 Jun; 77(11):1957-60. PubMed ID: 9667674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
    Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
    Di Felice G; Fumagalli L; Majorca F; Barni S; Ardizzoia A; Tancini G; Lissoni P
    J Biol Regul Homeost Agents; 1996; 10(4):98-9. PubMed ID: 9604779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
    Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
    J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
    Bonfanti A; Lissoni P; Bucovec R; Rovelli F; Brivio F; Fumagalli L
    Int J Biol Markers; 2000; 15(2):161-4. PubMed ID: 10883890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
    Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
    Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma.
    Lissoni P; Barni S; Ardizzoia A; Crispino S; Paolorossi F; Andres M; Scardino E; Tancini G
    Oncology; 1994; 51(1):59-62. PubMed ID: 8265104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
    Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
    Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy with low-dose subcutaneous interleukin-2 in metastatic renal carcinoma].
    Lissoni P; Barni S; Tancini G; Andres M; Scardino E; Cardellini P; Frascaroli M; Ardizzoia A; Crispino S; Vicini D
    Arch Ital Urol Androl; 1993 Apr; 65(2):123-8. PubMed ID: 8330055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy for metastatic renal carcinoma with interleukin-2 in a subcutanous administration schedule of short duration. Subcutaneous IL-2 in renal carcinoma].
    Lissoni P; Barni S; Ardizzoia A; Paolorossi F; Tancini G; Andres M; Favini P; Scardino E; Rocco F
    Arch Ital Urol Androl; 1997 Jun; 69(3):159-62. PubMed ID: 9273090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma].
    Viganò MG; Lissoni P; Barni S; Tancini G; Scardino E; Favini P; Baccalini A; Verweij F; Strada G; Rocco F
    Arch Ital Urol Androl; 1995 Apr; 67(2):143-7. PubMed ID: 7787856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma].
    Lissoni P; Barni S; Tancini G; Cazzaniga M; Frigerio F; Chilelli M; Scardino E; Andres M; Favini P; Meroni T; Verwei F; Baccalin A; Sala M; Frea B; Kocjancic E; Rocco F
    Arch Ital Urol Androl; 1997 Feb; 69(1):41-7. PubMed ID: 9181905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1.
    Lissoni P; Barni S; Ardizzoia A; Frigerio F; Paolorossi F; Cazzaniga M; Tancini G; Rocco F; Aapro M
    Tumori; 1995; 81(4):261-4. PubMed ID: 8540123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic predictive factors of the clinical response to immunotherapy with subcutaneous interleukin-2, in patients with metastatic renal carcinoma: analysis of 60 cases].
    Lissoni P; Scardino E; Favini P; Barni S; Tancini G; Baccalin A; Verweij F; Strada G; Musci R; Rocco F
    Arch Ital Urol Androl; 1995 Apr; 67(2):149-53. PubMed ID: 7787857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerations.
    Lissoni P; Rovelli F; Mandalà M; Barni S
    Int J Biol Markers; 1998; 13(3):169-71. PubMed ID: 10079393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preoperative subcutaneous immunotherapy with interleukin-2 in renal carcinoma with synchronous metastasis: randomized clinico-biological study. Preoperative use of Il-2 in renal carcinoma].
    Scardino E; Lissoni P; Andres M; Frea B; Favini P; Kocjancic E; Verweij F; Barani S; Tancini G; Rocco F
    Arch Ital Urol Androl; 1997 Feb; 69(1):49-54. PubMed ID: 9181906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
    Bordin V; Giani L; Meregalli S; Bukovec R; Vaghi MM; Mandalà M; Paolorossi F; Ardizzoia A; Tancini G; Barni S; Frigerio F; Fumagalli L; Bordoni A; Valsuani G; Di Felice G; Lissoni P
    Urol Int; 2000; 64(1):3-8. PubMed ID: 10782024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.